2021 |
08/11 | 4,660 | 4,747 | 4,659 | 4,720 | +1.9% | 738,100 | 2兆6329億 | +5.78% |
08/10 | 4,445 | 4,665 | 4,438 | 4,632 | +5.39% | 1,147,700 | 2兆5838億 | +3.95% |
08/06 | 13:30 2021年12月期第2四半期決算短信〔IFRS〕(連結) |
08/06 | 4,335 | 4,452 | 4,330 | 4,395 | +1.2% | 914,400 | 2兆4516億 | -1.35% |
08/05 | 4,353 | 4,381 | 4,338 | 4,343 | -0.53% | 394,400 | 2兆4226億 | -2.69% |
08/04 | 4,420 | 4,430 | 4,353 | 4,366 | -0.8% | 528,900 | 2兆4355億 | -2.44% |
08/03 | 4,405 | 4,436 | 4,391 | 4,401 | -1.59% | 497,100 | 2兆4550億 | -1.98% |
08/02 | 4,400 | 4,487 | 4,391 | 4,472 | +3.09% | 737,700 | 2兆4946億 | -0.69% |
07/30 | 4,443 | 4,448 | 4,338 | 4,338 | -2.76% | 663,600 | 2兆4198億 | -3.9% |
07/29 | 4,493 | 4,517 | 4,446 | 4,461 | -0.22% | 665,500 | 2兆4885億 | -1.5% |
07/28 | 4,478 | 4,483 | 4,453 | 4,471 | -0.36% | 408,600 | 2兆4940億 | -1.54% |
07/27 | 4,513 | 4,527 | 4,472 | 4,487 | -0.42% | 467,500 | 2兆5030億 | -1.25% |
07/26 | 4,570 | 4,570 | 4,477 | 4,506 | +0.92% | 571,300 | 2兆5136億 | -1.03% |
07/21 | 4,486 | 4,514 | 4,451 | 4,465 | +0.65% | 432,300 | 2兆4907億 | -2.08% |
07/20 | 4,438 | 4,470 | 4,404 | 4,436 | -0.87% | 618,500 | 2兆4745億 | -2.97% |
07/19 | 4,485 | 4,485 | 4,427 | 4,475 | -0.22% | 587,100 | 2兆4963億 | -2.42% |
07/16 | 4,468 | 4,519 | 4,441 | 4,485 | +0.13% | 790,900 | 2兆5018億 | -2.44% |
07/15 | 4,481 | 4,566 | 4,473 | 4,479 | -1.58% | 870,600 | 2兆4985億 | -2.78% |
07/14 | 4,487 | 4,580 | 4,480 | 4,551 | +1.43% | 1,018,100 | 2兆5387億 | -1.39% |
07/13 | 4,430 | 4,509 | 4,411 | 4,487 | +2.21% | 922,400 | 2兆5030億 | -2.86% |
07/12 | 4,415 | 4,420 | 4,347 | 4,390 | +2% | 1,070,400 | 2兆4488億 | -5.1% |
07/09 | 4,275 | 4,312 | 4,226 | 4,304 | +0.12% | 1,768,500 | 2兆4009億 | -7.12% |
07/08 | 4,365 | 4,373 | 4,279 | 4,299 | -4.47% | 2,418,700 | 2兆3981億 | -7.47% |
07/07 | 4,475 | 4,505 | 4,427 | 4,500 | -0.9% | 844,500 | 2兆5102億 | -3.39% |
07/06 | 4,552 | 4,583 | 4,506 | 4,541 | +0.04% | 739,700 | 2兆5331億 | -2.51% |
07/05 | 4,563 | 4,591 | 4,535 | 4,539 | -0.68% | 546,300 | 2兆5320億 | -2.51% |
07/02 | 4,625 | 4,644 | 4,550 | 4,570 | -0.91% | 598,700 | 2兆5493億 | -1.83% |
07/01 | 4,600 | 4,637 | 4,577 | 4,612 | +0.11% | 636,800 | 2兆5727億 | -0.95% |
06/30 | 4,677 | 4,677 | 4,601 | 4,607 | -0.67% | 707,300 | 2兆5699億 | -1.01% |
06/29 | 4,667 | 4,667 | 4,595 | 4,638 | -1.95% | 906,700 | 2兆5872億 | -0.24% |
06/28 | 4,770 | 4,770 | 4,692 | 4,730 | -0.19% | 736,400 | 2兆6385億 | +1.9% |
06/25 | 4,752 | 4,774 | 4,719 | 4,739 | +0.21% | 583,900 | 2兆6435億 | +2.31% |
06/24 | 4,701 | 4,738 | 4,678 | 4,729 | -0.08% | 609,600 | 2兆6380億 | +2.38% |
06/23 | 4,747 | 4,793 | 4,723 | 4,733 | -0.32% | 658,700 | 2兆6402億 | +2.76% |
06/22 | 4,646 | 4,764 | 4,619 | 4,748 | +4.24% | 1,172,500 | 2兆6486億 | +3.35% |
06/21 | 4,564 | 4,581 | 4,512 | 4,555 | -3.17% | 1,023,700 | 2兆5409億 | -0.59% |
06/18 | 4,713 | 4,723 | 4,673 | 4,704 | +0.43% | 1,416,300 | 2兆6240億 | +2.77% |
06/17 | 4,757 | 4,774 | 4,666 | 4,684 | -1.53% | 759,900 | 2兆6129億 | +2.63% |
06/16 | 4,794 | 4,806 | 4,742 | 4,757 | -0.69% | 757,400 | 2兆6536億 | +4.64% |
06/15 | 4,750 | 4,801 | 4,731 | 4,790 | +0.78% | 701,400 | 2兆6720億 | +5.86% |
06/14 | 4,750 | 4,759 | 4,719 | 4,753 | +0.49% | 601,600 | 2兆6513億 | +5.5% |
06/11 | 4,696 | 4,747 | 4,670 | 4,730 | +0.75% | 1,125,500 | 2兆6385億 | +5.35% |
06/10 | 4,625 | 4,707 | 4,623 | 4,695 | +0.95% | 746,300 | 2兆6190億 | +4.96% |
06/09 | 4,670 | 4,678 | 4,617 | 4,651 | -0.04% | 536,800 | 2兆5944億 | +4.4% |
06/08 | 4,650 | 4,672 | 4,600 | 4,653 | +1.13% | 880,900 | 2兆5956億 | +4.87% |
06/07 | 4,619 | 4,660 | 4,578 | 4,601 | -0.07% | 643,400 | 2兆5666億 | +4.1% |
06/04 | 4,603 | 4,610 | 4,554 | 4,604 | +0.63% | 742,700 | 2兆5682億 | +4.49% |
06/03 | 4,560 | 4,618 | 4,551 | 4,575 | +1.33% | 924,400 | 2兆5520億 | +4.12% |
06/02 | 4,415 | 4,548 | 4,360 | 4,515 | +0.78% | 1,037,800 | 2兆5186億 | +2.99% |
06/01 | 19:00 腎性貧血治療薬「バダデュスタット」米国FDAが製造販売申請を受理 |
06/01 | 4,547 | 4,549 | 4,455 | 4,480 | -0.8% | 492,800 | 2兆4991億 | +2.4% |
05/31 | 4,580 | 4,594 | 4,512 | 4,516 | -1.95% | 687,400 | 2兆5191億 | +3.44% |
05/28 | 4,586 | 4,635 | 4,563 | 4,606 | +1.08% | 1,482,700 | 2兆5693億 | +5.74% |
05/27 | 4,475 | 4,560 | 4,465 | 4,557 | +1.79% | 2,599,200 | 2兆5420億 | +4.86% |
05/26 | 4,424 | 4,495 | 4,416 | 4,477 | +0.16% | 932,600 | 2兆4974億 | +3.23% |
05/25 | 4,493 | 4,494 | 4,446 | 4,470 | 0% | 937,800 | 2兆4935億 | +3.23% |
05/24 | 4,413 | 4,502 | 4,411 | 4,470 | +0.86% | 616,300 | 2兆4935億 | +3.33% |
05/21 | 4,427 | 4,456 | 4,407 | 4,432 | +1.03% | 796,300 | 2兆4723億 | +2.36% |
05/20 | 4,395 | 4,422 | 4,370 | 4,387 | -1.17% | 695,100 | 2兆4472億 | +1.22% |
05/19 | 4,405 | 4,456 | 4,369 | 4,439 | -0.49% | 917,100 | 2兆4762億 | +2.3% |
05/18 | 4,439 | 4,487 | 4,411 | 4,461 | +1.04% | 886,700 | 2兆4885億 | +2.76% |
05/17 | 4,400 | 4,427 | 4,371 | 4,415 | +0.59% | 613,500 | 2兆4628億 | +1.61% |
05/14 | 4,231 | 4,416 | 4,230 | 4,389 | +4.05% | 1,084,500 | 2兆4483億 | +0.85% |
05/13 | 13:30 2021年12月期第1四半期決算短信〔IFRS〕(連結) |
05/13 | 4,243 | 4,268 | 4,195 | 4,218 | -0.71% | 779,900 | 2兆3529億 | -3.32% |
05/12 | 4,288 | 4,306 | 4,210 | 4,248 | -0.75% | 753,600 | 2兆3696億 | -3.04% |
05/11 | 4,375 | 4,396 | 4,259 | 4,280 | -2.37% | 879,600 | 2兆3875億 | -2.71% |
05/10 | 4,323 | 4,391 | 4,323 | 4,384 | +2.02% | 624,200 | 2兆4455億 | -0.7% |
05/07 | 4,267 | 4,338 | 4,245 | 4,297 | +0.89% | 762,500 | 2兆3970億 | -3% |
05/06 | 4,276 | 4,309 | 4,247 | 4,259 | +1.38% | 1,099,100 | 2兆3758億 | -4.29% |
04/30 | 4,195 | 4,231 | 4,182 | 4,201 | -0.38% | 893,600 | 2兆3434億 | -6.02% |
04/28 | 15:00 譲渡制限付株式報酬としての自己株式の処分の払込完了に関するお知らせ |
04/28 | 4,204 | 4,240 | 4,183 | 4,217 | -0.61% | 785,900 | 2兆3523億 | -6.02% |
04/27 | 4,330 | 4,333 | 4,241 | 4,243 | -1.6% | 905,300 | 2兆3668億 | -5.73% |
04/26 | 4,294 | 4,335 | 4,262 | 4,312 | -0.25% | 784,200 | 2兆4053億 | -4.58% |
04/23 | 4,278 | 4,333 | 4,273 | 4,323 | +0.56% | 737,700 | 2兆4115億 | -4.65% |
04/22 | 4,278 | 4,304 | 4,232 | 4,299 | +1.3% | 815,300 | 2兆3981億 | -5.58% |
04/21 | 4,231 | 4,254 | 4,195 | 4,244 | -0.77% | 1,035,200 | 2兆3674億 | -7.15% |
04/20 | 4,329 | 4,335 | 4,269 | 4,277 | -1.72% | 828,300 | 2兆3858億 | -6.8% |
04/19 | 4,330 | 4,368 | 4,316 | 4,352 | +0.65% | 578,300 | 2兆4277億 | -5.51% |
04/16 | 4,362 | 4,365 | 4,324 | 4,324 | +0.3% | 829,000 | 2兆4120億 | -6.37% |
04/15 | 4,379 | 4,386 | 4,311 | 4,311 | -1.21% | 995,400 | 2兆4048億 | -6.87% |
04/14 | 4,500 | 4,500 | 4,357 | 4,364 | -4.51% | 1,584,300 | 2兆4343億 | -5.89% |
04/13 | 15:00 抗精神病薬「ブレクスピプラゾール」アルツハイマー型認知症に伴う行動障害(アジテーション)を対象としたグローバルフェーズ3試験の中間解析結果について |
04/13 | 4,536 | 4,611 | 4,536 | 4,570 | +0.75% | 678,000 | 2兆5493億 | -1.64% |
04/12 | 4,557 | 4,572 | 4,524 | 4,536 | +0.44% | 671,500 | 2兆5303億 | -2.37% |
04/09 | 4,525 | 4,565 | 4,484 | 4,516 | +0.76% | 1,077,700 | 2兆5191億 | -2.69% |
04/08 | 4,570 | 4,572 | 4,475 | 4,482 | -1.82% | 690,000 | 2兆5002億 | -3.32% |
04/07 | 4,575 | 4,605 | 4,532 | 4,565 | -0.33% | 610,700 | 2兆5465億 | -1.36% |
04/06 | 4,693 | 4,704 | 4,576 | 4,580 | -1.84% | 778,100 | 2兆5548億 | -0.84% |
04/05 | 4,702 | 4,715 | 4,646 | 4,666 | -0.32% | 663,800 | 2兆6028億 | +1.26% |
04/02 | 4,715 | 4,726 | 4,656 | 4,681 | -0.09% | 471,500 | 2兆6112億 | +1.87% |
04/01 | 4,740 | 4,760 | 4,677 | 4,685 | -0.04% | 641,200 | 2兆6134億 | +2.36% |
03/31 | 4,704 | 4,751 | 4,684 | 4,687 | -1.51% | 869,300 | 2兆6145億 | +2.67% |
03/30 | 19:00 腎性貧血治療薬「バダデュスタット」米国で製造販売申請を提出 |
03/30 | 16:30 譲渡制限付株式報酬としての自己株式の処分に関するお知らせ |
03/30 | 4,837 | 4,838 | 4,722 | 4,759 | -0.94% | 764,300 | 2兆6547億 | +4.5% |
03/29 | 4,772 | 4,839 | 4,750 | 4,804 | +1.2% | 1,440,700 | 2兆6798億 | +5.75% |
03/26 | 4,713 | 4,775 | 4,704 | 4,747 | +2.24% | 893,000 | 2兆6480億 | +4.81% |
03/25 | 4,619 | 4,661 | 4,583 | 4,643 | +1.82% | 763,700 | 2兆5900億 | +2.72% |
03/24 | 4,661 | 4,687 | 4,551 | 4,560 | -2.63% | 736,400 | 2兆5437億 | +1.02% |
03/23 | 4,726 | 4,728 | 4,682 | 4,683 | -0.04% | 645,300 | 2兆6123億 | +3.77% |
03/22 | 4,756 | 4,794 | 4,653 | 4,685 | -2.7% | 864,200 | 2兆6134億 | +3.95% |
03/19 | 4,744 | 4,820 | 4,685 | 4,815 | +1.41% | 1,180,400 | 2兆6859億 | +6.93% |
03/18 | 4,700 | 4,777 | 4,687 | 4,748 | +1.5% | 814,400 | 2兆6486億 | +5.58% |
03/17 | 4,647 | 4,690 | 4,618 | 4,678 | -0.4% | 739,500 | 2兆6095億 | +4.09% |
03/16 | 4,661 | 4,706 | 4,619 | 4,697 | +0.56% | 942,500 | 2兆6201億 | +4.47% |